ALBANY, N.Y., March 30, 2016 /PRNewswire/ -- AMRI (NASDAQ:
AMRI) today announced that it has filed with the U.S. Securities
and Exchange Commission (SEC) its Annual Report on Form 10-K for
the year ended December 31,
2015. A copy of the Annual Report on Form 10-K is available
to be viewed or downloaded within the Investor Relations section of
the Company's website at www.amriglobal.com.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS
segment provides comprehensive services from hit identification to
IND, including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug metabolism and
pharmacokinetics, as well as natural products. API supports the
chemical development and cGMP manufacture of complex API, including
potent and cytotoxic compounds, controlled substances, steroids,
peptides, hormones, and sterile API. DPM supports development
through commercial scale production of complex liquid-filled and
lyophilized parenterals, sterile suspensions and ophthalmic
formulations. For more information about AMRI, please visit our
website at www.amriglobal.com or follow us on Twitter
(@amriglobal).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-announces-filing-of-annual-report-on-form-10k-300243285.html
SOURCE AMRI